Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Doxorubicin vs Docetaxel in Metastatic Breast Cancer
NCT00193037Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Feb 2001
- Primary completion
- Dec 2008
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegylated liposomal doxorubicin in breast cancer (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 18 months. Started Feb 2001; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00193037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193037.